![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Malar.
Sec. Vectors
Volume 3 - 2025 | doi: 10.3389/fmala.2025.1540884
This article is part of the Research Topic Addressing Contemporary Threats to Global Malaria Control: New Tools and Strategies View all 6 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The widespread development of pyrethroid-resistant Anopheles populations, has reduced the efficacy of pyrethroid insecticidetreated nets (ITNs), hindering malaria control efforts. This study tested PRONet Duo, a new ITN with two active ingredients-bifenthrin and chlorfenapyr. Bifenthrin is a fluorinated pyrethroid that is highly stable and more slowly detoxified by pyrethroid-resistant mosquitoes.Chlorfenapyr disrupts cellular energy production. The efficacy of PRONet Duo was compared to Interceptor ® G2, an alpha-cypermethrin and chlorfenapyr ITN with proven efficacy in malaria reduction.The study was conducted in two identical 9x9 Latin square experimental hut trials against wild free-flying Anopheles gambiae sensu lato in M'Bé, Côte d'Ivoire, and Lupiro, Tanzania using 18 experimental huts over 108 nights. The primary endpoint was the proportion of 72hour mosquito mortality (M72) and the secondary endpoint was the proportion of mosquito blood-feeding. The study was done following World Health Organization guidelines. Data were analysed using mixed-effect linear regression with a 7% margin of non-inferiority. Data were classified as non-inferior using delta and superior using the line of no difference.Results: PRONet Duo demonstrated a non-inferior and superior mosquito mortality compared to Interceptor ® G2 in both study sites. In Côte d'Ivoire, the M72 of PRONet Duo was 84% [81,88], higher than that of Interceptor ® G2 (72% [68,76], OR: 1. 54 [1.27,1.88]) and it was superior to MAGNet ® (30% [27,34], OR: 13.74 [11.35,16.63], p<0.0001). In Tanzania, M72 of PRONet Duo was 68% [62,73], higher than that induced by Interceptor ® G2 (44% [40,49], Odds Ratio (OR):1.74 [1.54,1.96]), and MAGNet ® (36% [32,41], OR:4.82 [4.06,5.72] p<0.0001). PRONet Duo also induced non-inferior and superior prevention of blood-feeding compared to Interceptor ® G2, with less than 11% feeding success observed in either trial site.PRONet Duo ITNs are non-inferior and superior to the first-in-class Interceptor ® G2 in terms of mosquito mortality and prevention of blood-feeding demonstrating the added benefit of bifenthrin for insecticide resistance management. Both chlorfenapyr nets offered superior mortality compared to the pyrethroid-only ITN. PRONet Duo offers an additional highly effective ITN for control of pyrethroid-resistant mosquitoes in malaria endemic regions
Keywords: Anopheles gambiae, Anopheles coluzzii, Anopheles arabiensis, non-inferiority, chlorfenapyr, Bifenthrin, PRONet Duo, Interceptor ® G2
Received: 06 Dec 2024; Accepted: 13 Feb 2025.
Copyright: © 2025 Assenga, Ahoua Alou, Camara, Koffi, N'guessan, Kamande, Ngonyani, Kibondo, Odufuwa, Ntabaliba, Lekundayo, Abilah, Madumla, Muganga, Moore and Moore. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Alphonce Assenga, Ifakara Health Institute, Ifakara, Tanzania
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.